Cases & Deals

Pfizer is involved in joint venture with GlaxoSmithKline to create new world-leading HIV company focused on research, development and commercialization of HIV medicines

Clients Pfizer, Inc.

Jones Day represented Pfizer, Inc. in its agreement with GlaxoSmithKline plc to create a new world-leading HIV company focused solely on research, development and commercialization of HIV medicines. GlaxoSmith Kline will initially hold an 85% equity interest in the new company and Pfizer will hold 15%. The transaction is expected to close in the fourth quarter of 2009.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.